Preclinical News and Research

RSS

CNBG, Aeras sign MOU to develop TB vaccines in China and around the world

Aeras and the China National Biotech Group (CNBG) today announced the signing of a memorandum of understanding for the organizations to pursue opportunities to jointly develop tuberculosis (TB) vaccines in China and potentially other parts of the world.

26 Jul 2011

Adaptimmune announces opening of pilot clinical trial in synovial sarcoma

Adaptimmune announced today that it has opened a Pilot, open-label clinical trial in synovial sarcoma at the National Cancer Institute (NCI), Bethesda, Maryland, testing its enhanced T cell receptor T cell therapy. A second site is planned to open later this year at Washington University, St. Louis, Missouri.

25 Jul 2011

Promising drug for Duchenne muscular dystrophy

Duchenne muscular dystrophy is a severely debilitating and lethal condition that affects 1 in 3,000. Females and males are affected, though females are rarely affected and are more often carriers. It is caused due to a defective gene that normally codes for the protein dystrophin, which helps provide a protective membrane around muscle fibers. Without this skin, muscle fibers become damaged and eventually die.

25 Jul 2011

Nanoviricides lead anti-HIV candidate as good as HAART cocktail therapy

NanoViricides, Inc. reports that its lead anti-HIV candidate achieved anti-HIV efficacy equivalent to a HAART triple drug cocktail in its recently completed animal study.

25 Jul 2011

Researchers examine benefits of hyperbaric oxygen in treatment of aggressive brain cancer

In a unique study, researchers at The Long Island Brain Tumor Center at Neurological Surgery, P.C. are examining whether hyperbaric oxygen therapy - breathing pure oxygen while in a pressurized chamber - may prove a useful addition to the current standard of care for patients newly diagnosed with glioblastoma, an aggressive brain cancer.

22 Jul 2011

SG Austria acquisition benefits Nuvilex with $1.5M in grant funding

Nuvilex, Inc. announced today that as part of its acquisition of SG Austria, Nuvilex will benefit from grant funding previously awarded to SG Austria for its live-cell encapsulation activities and other projects. The total grant funding awarded to SG Austria is approximately $1.5 million.

22 Jul 2011

FDA approves U.S. launch of Wiskott-Aldrich gene therapy clinical trial

The U.S. Food & Drug Administration (FDA) approved the launching in the U.S. of a clinical trial for gene therapy for a rare immunodeficiency, Wiskott-Aldrich syndrome.

22 Jul 2011

Quest receives U.S. patent allowance for cancer combination therapy

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced that it has received notice of allowance for U.S. Patent Application 10/831,886 entitled: "Combination Therapy for Treating Disease".

22 Jul 2011

Adamis receives U.S. patent for APC-100 to treat prostate cancer

Adamis Pharmaceuticals Corporation, today announced the technology which constitutes its compound APC-100 was recently granted a patent in the United States.

22 Jul 2011

Bristol-Myers Squibb signs definitive agreement to acquire Amira Pharmaceuticals

Bristol-Myers Squibb Company and Amira Pharmaceuticals, Inc., announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire privately held Amira Pharmaceuticals, a small-molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases.

22 Jul 2011

Galectin, University of Michigan enter collaboration to study role of Galectins in cardiovascular disease

Galectin Therapeutics Inc. today announced that it has entered into a research collaboration with Dr. Jose Jalife of the University of Michigan Medical School to better understand the relationship of Galectin-3 to cardiac fibrosis in chronic cardiac arrhythmias.

21 Jul 2011

Identification of third microRNA target triggers milestone payment from GSK to Regulus

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has identified a third microRNA target in its alliance with GlaxoSmithKline (GSK), triggering a preclinical milestone payment from GSK.

21 Jul 2011

Falling may be an early sign of Alzheimer's

In a new study presented at the Alzheimer's Association's annual International Conference in Paris it was reported that older people whose brain scans showed signs of amyloid plaques - an early indicator of Alzheimer's disease - but who were otherwise healthy, had twice the risk of falls as people without brain amyloid.

20 Jul 2011

Alzheimer’s risk transmitted from mother to offspring: Study report

According to preliminary research adults whose mothers develop late-onset Alzheimer's disease may have an increased risk for the disease, compared with children of dads with late-onset Alzheimer's. The findings were presented at the Alzheimer's Association International Conference 2011.

20 Jul 2011

New anti-cancer drugs plus chemo for breast cancer shows promise: Study

Melbourne researchers have discovered that some of the most aggressive forms of cancers can be more effectively treated if chemotherapy is combined with a new class of anti-cancer drugs.

20 Jul 2011

Latest advances in Alzheimer's research presented at AAIC 2011

This week, more than 5,000 scientists from around the world gathered in Paris to report the latest advances in Alzheimer's research at the Alzheimer's Association International Conference 2011.

20 Jul 2011

Chemotherapy combined with anti-cancer agent shows promise for treatment of aggressive breast cancers

Some of the most aggressive forms of breast cancer are more vulnerable to chemotherapy when it is combined with a new class of anti-cancer agent, researchers from the Walter and Eliza Hall Institute have shown.

20 Jul 2011

New transgenic mouse could predict toxicity of targeted cancer drugs

Only one in twenty cancer drugs makes its way from the laboratory to become an approved pharmaceutical product. The majority of new agents are only shown to be unsuitable in the later phases of clinical development which would explain the exorbitantly high development costs of 500 to 600 million euros per new cancer drug.

20 Jul 2011

Falls, balance problems linked to early stages of Alzheimer's

Falls and balance problems may be early indicators of Alzheimer's disease, researchers at Washington University School of Medicine in St. Louis reported July 17, 2011, at the Alzheimer's Association International Conference on Alzheimer's Disease in Paris.

20 Jul 2011

Altogen Labs introduces pyrosequencing services for hospitals, research institutions

Altogen Labs, a biology contract research organization and provider of pre-clinical research services, announced its launch of a pyrosequencing service today.

20 Jul 2011